b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30120163</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>03</Month>\n            <Day>24</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>03</Month>\n            <Day>24</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1549-490X</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>24</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>01</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>The oncologist</Title>\n                <ISOAbbreviation>Oncologist</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>103-109</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2018-0221</ELocationID>\n            <Abstract>\n                <AbstractText>On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab (Keytruda, Merck &amp; Co., Inc., Whitehouse Station, NJ) for the treatment of patients with recurrent, locally advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after two or more systemic therapies, including fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, HER2/neu-targeted therapy, and whose tumors express programmed death-ligand 1 (PD-L1), as determined by an FDA-approved test. Approval was based on demonstration of durable overall response rate (ORR) in a multicenter, open-label, multicohort trial (KEYNOTE-059/Cohort 1) that enrolled 259 patients with locally advanced or metastatic gastric or GEJ adenocarcinoma. Among the 55% (<i>n</i> = 143) of patients whose tumors expressed PD-L1 based on a combined positive score \xe2\x89\xa51 and either were microsatellite stable or had undetermined microsatellite instability or mismatch repair status, the confirmed ORR as determined by blinded independent central review was 13.3% (95% CI, 8.2-20.0); 1.4% had complete responses. Response durations ranged from 2.8+ to 19.4+ months; 11 patients (58%) had response durations of 6 months or longer, and 5 patients (26%) had response durations of 12 months or longer. The most common (\xe2\x89\xa520%) adverse reactions of pembrolizumab observed in KEYNOTE-059/Cohort 1 were fatigue, decreased appetite, nausea, and constipation. The most frequent (\xe2\x89\xa52%) serious adverse drug reactions were pleural effusion, pneumonia, dyspnea, pulmonary embolism, and pneumonitis. Pembrolizumab was approved concurrently with the PD-L1 immunohistochemistry 22C3 pharmDx test (Dako, Agilent, Santa Clara, CA) for selection of patients with gastric cancer for treatment with pembrolizumab based on PD-L1 tumor expression. IMPLICATIONS FOR PRACTICE: This report presents key information on the basis for Food and Drug Administration approval of pembrolizumab for the treatment of patients with locally advanced or metastatic gastric or GEJ adenocarcinoma whose tumors express PD-L1. The report discusses the basis for limiting the indication to patients with PD-L1-expressing tumors and the basis for recommending that PD-L1 status be assessed using a fresh tumor specimen if PD-L1 expression is not detected in an archival gastric or GEJ cancer specimen.</AbstractText>\n                <CopyrightInformation>Published 2018. This article is a U.S. Government work and is in the public domain in the USA.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Fashoyin-Aje</LastName>\n                    <ForeName>Lola</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, Maryland, USA lola.fashoyin-aje@fda.hhs.gov.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Donoghue</LastName>\n                    <ForeName>Martha</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chen</LastName>\n                    <ForeName>Huanyu</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>He</LastName>\n                    <ForeName>Kun</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Veeraraghavan</LastName>\n                    <ForeName>Janaki</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Goldberg</LastName>\n                    <ForeName>Kirsten B</ForeName>\n                    <Initials>KB</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Keegan</LastName>\n                    <ForeName>Patricia</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>McKee</LastName>\n                    <ForeName>Amy E</ForeName>\n                    <Initials>AE</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pazdur</LastName>\n                    <ForeName>Richard</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>08</Month>\n                <Day>17</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Oncologist</MedlineTA>\n            <NlmUniqueID>9607837</NlmUniqueID>\n            <ISSNLinking>1083-7159</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>DPT0O3T46P</RegistryNumber>\n                <NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <SupplMeshList>\n            <SupplMeshName Type="Disease" UI="C562730">Adenocarcinoma Of Esophagus</SupplMeshName>\n        </SupplMeshList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004938" MajorTopicYN="N">Esophageal Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004943" MajorTopicYN="N">Esophagogastric Junction</DescriptorName>\n                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Accelerated approval</Keyword>\n            <Keyword MajorTopicYN="Y">GEJ adenocarcinoma</Keyword>\n            <Keyword MajorTopicYN="Y">PD\xe2\x80\x90L1</Keyword>\n        </KeywordList>\n        <CoiStatement>Disclosures of potential conflicts of interest may be found at the end of this article.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>04</Month>\n                <Day>11</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>05</Month>\n                <Day>31</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>8</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>8</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30120163</ArticleId>\n            <ArticleId IdType="pii">theoncologist.2018-0221</ArticleId>\n            <ArticleId IdType="doi">10.1634/theoncologist.2018-0221</ArticleId>\n            <ArticleId IdType="pmc">PMC6324629</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Ann Oncol. 2009 Oct;20(10):1667-73</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19549707</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2016 Aug 10;34(23):2736-42</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27382098</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2012 May 1;30(13):1513-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22412140</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2014 Jan;15(1):78-86</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24332238</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Treat Rev. 2010 Aug;36(5):384-92</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20176443</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Oncol. 2009 Apr;20(4):666-73</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19153121</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Cancer. 2012 Mar;48(4):518-26</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22243774</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2008 Mar 20;26(9):1435-42</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18349393</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>CA Cancer J Clin. 2017 Jan;67(1):7-30</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28055103</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Cancer. 2011 Oct;47(15):2306-14</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21742485</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Semin Radiat Oncol. 2002 Apr;12(2):111-27</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11979413</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2014 Oct;15(11):1224-35</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25240821</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2004 Nov 1;22(21):4319-28</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15514373</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'